FDA-cleared profile

Auto Segmentation

GE Medical Systems, LLC · Radiotherapy Planning Imaging · FDA-cleared (510(k))

Authorized purpose: Auto Segmentation generates initial DICOM RT Structure Set contours for 40 organs or subregions from adult contrast or noncontrast CT across head and neck, thorax, abdomen, and pelvis; qualified radiotherapy staff must review labels and edit contours before planning.

Clinical role
Automatic initial organ-at-risk contouring before qualified review and editing.
Images and patients
Radiotherapy Planning Imaging · Multi-region
Key limitation
Keep in mind: It is the responsibility of the user to verify the processed output contours and user-defined labels for each organ at risk and correct the contours/labels as needed. Auto Segmentation may be used with images acquired on CT scanners, in adult patients.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Auto Segmentation generates initial DICOM RT Structure Set contours for 40 organs or subregions from adult contrast or noncontrast CT across head and neck, thorax, abdomen, and pelvis; qualified radiotherapy staff must review labels and edit contours before planning.
  • Which images or clinical context are in scope?Modality: Radiotherapy Planning Imaging Anatomy or clinical context: Multi-region Input: Adult single-energy DICOM CT images from GE or non-GE scanners.
  • Who uses it?Intended users: Dosimetrists, medical physicists, radiation oncologists, and qualified radiotherapy practitioners.
  • What does the software produce?Output: DICOM RT Structure Set contours and labels routed to configured review workstations.
  • What is its most important limitation?Key limitation: It is the responsibility of the user to verify the processed output contours and user-defined labels for each organ at risk and correct the contours/labels as needed. Auto Segmentation may be used with images acquired on CT scanners, in adult patients.

Clinical takeaway. Clinical role: Auto Segmentation generates initial DICOM RT Structure Set contours for 40 organs or subregions from adult contrast or noncontrast CT across head and neck, thorax, abdomen, and pelvis; qualified radiotherapy staff must review labels and edit contours before planning.

Evidence takeaway. Evidence from the reviewed source record: K230082 reports training on 911 CT examinations and independent testing on 302 exams from nine global sources, producing 2,552 expert-referenced contours. Three radiotherapy practitioners established references and separately reviewed clinical adequacy; organ-level Dice results ranged widely, reinforcing the need for structure-specific acceptance.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Auto Segmentation generates initial DICOM RT Structure Set contours for 40 organs or subregions from adult contrast or noncontrast CT across head and neck, thorax, abdomen, and pelvis; qualified radiotherapy staff must review labels and edit contours before planning.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.

Workflow role
Automatic initial organ-at-risk contouring before qualified review and editing.
  • Exact FDA submission
  • Checked 2026-09-03
Required input
Adult single-energy DICOM CT images from GE or non-GE scanners.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Output and clinician action
DICOM RT Structure Set contours and labels routed to configured review workstations.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Care setting
Radiation-oncology planning departments using compatible CT and RT Structure Set review systems.
  • Exact FDA submission
  • Checked 2026-09-03
Intended users
Dosimetrists, medical physicists, radiation oncologists, and qualified radiotherapy practitioners.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Limitations
It is the responsibility of the user to verify the processed output contours and user-defined labels for each organ at risk and correct the contours/labels as needed. Auto Segmentation may be used with images acquired on CT scanners, in adult patients.
  • Exact FDA submission
  • Checked 2026-09-19

The exact indications text establishes user verification, correction, and the adult CT boundary; the dossier's Dice-to-editing and dosimetric-acceptability conclusion is not stated in the packet.

Evidence summary
K230082 reports training on 911 CT examinations and independent testing on 302 exams from nine global sources, producing 2,552 expert-referenced contours. Three radiotherapy practitioners established references and separately reviewed clinical adequacy; organ-level Dice results ranged widely, reinforcing the need for structure-specific acceptance.
  • Exact FDA submission
  • Checked 2026-09-03

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K230082 reports training on 911 CT examinations and independent testing on 302 exams from nine global sources, producing 2,552 expert-referenced contours. Three radiotherapy practitioners established references and separately reviewed clinical adequacy; organ-level Dice results ranged widely, reinforcing the need for structure-specific acceptance.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Sensitivity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or quantitative-biomarker function. Use the task-specific endpoints and tested population reported below.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Specificity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or quantitative-biomarker function. Use the task-specific endpoints and tested population reported below.

Independent validation exams

302 exams

  • EndpointOrgan-at-risk segmentation
  • PopulationAuto Segmentation
  • Tested versionGE Auto Segmentation release cleared in K230082

Evaluated contours

2552 contours

  • EndpointComparison with expert ground truth
  • PopulationAuto Segmentation
  • Tested versionGE Auto Segmentation release cleared in K230082

Liver mean Dice

94.28 %

  • EndpointLiver segmentation
  • PopulationAuto Segmentation
  • Tested versionGE Auto Segmentation release cleared in K230082

Whole-brain mean Dice

98.53 %

  • EndpointWhole-brain segmentation
  • PopulationAuto Segmentation
  • Tested versionGE Auto Segmentation release cleared in K230082

Chiasm mean Dice

43.81 %

  • EndpointChiasm segmentation
  • PopulationAuto Segmentation
  • Tested versionGE Auto Segmentation release cleared in K230082

K230082 FDA performance package for Auto Segmentation

  • DesignManufacturer independent multicenter bench validation and blinded three-reader qualitative contour-adequacy study
  • Population302 adult radiotherapy-planning CT exams from North America, Europe, and Asia
  • Scopeexact submission
  • Tested versionGE Auto Segmentation release cleared in K230082
  • Samplen=302
  • Sites9
  • IndependenceSponsor or vendor study

K230082

Manufacturer evidence submitted for substantial equivalence; local clinical, technical, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K230082 by exact submission identifier.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03

A zero-result exact-identifier search does not prove that no recall, correction, adverse-event report, or product-family safety signal exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS radiation-oncology material. Evaluate net planning or delivery value within the radiotherapy service line.
  • Service-level, not product-specific
  • Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Adult single-energy DICOM CT images from GE or non-GE scanners.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K230082: Auto Segmentation

  2. Routing

    Source context, not route validation: Server-based automated DICOM CT ingestion and RTSS export to predefined destinations; test scanner protocols, contrast, slice spacing, structure naming, routing, TPS import, and failure quarantine.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-03 · FDA K230082: Auto Segmentation · Auto Segmentation for radiation therapy planning

  3. AI processing

    Source context, not route validation: Server-based software integrated with qualified GE CT and radiotherapy review workflows; exact supported infrastructure and service boundaries require vendor confirmation.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-03 · FDA K230082: Auto Segmentation · Auto Segmentation for radiation therapy planning

  4. Returned objects

    Source context, not route validation: DICOM RT Structure Set contours and labels routed to configured review workstations.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K230082: Auto Segmentation

  5. Viewer/worklist/report

    Unresolved route: DICOM RT Structure Set contours and labels routed to configured review workstations.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K230082: Auto Segmentation

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Server-based software integrated with qualified GE CT and radiotherapy review workflows; exact supported infrastructure and service boundaries require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-09-03
Integration
Server-based automated DICOM CT ingestion and RTSS export to predefined destinations; test scanner protocols, contrast, slice spacing, structure naming, routing, TPS import, and failure quarantine.
  • Exact FDA submission
  • Checked 2026-09-03
Security
GE HealthCare's Product Security Portal is described as a credentialed global portal giving customers security updates, vulnerability status and required actions for GE HealthCare products potentially impacted by critical vulnerabilities, plus historical patch views; GE HealthCare references its Cybersecurity Risk Management System and publishes a Coordinated Vulnerability Disclosure Statement for reporting vulnerabilities in GE HealthCare products.
  • Vendor-wide
  • Checked 2026-10-26

Vendor statement, not an attestation. Identity bridge: GE HealthCare's own Privacy Shield page on gehealthcare.com names GE Medical Systems LLC as a US entity of the GEHC group. Corporate program statement; portal content is credentialed; exact-release scope is not established.

Training
Only dosimetrists, medical physicists, radiation oncologists, and qualified radiotherapy practitioners. should operate or interpret the system. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-03
Monitoring
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: The software is for adults and initial segmentation only. Users must verify every contour and label; average Dice varies greatly by structure and does not predict local editing burden or dosimetric acceptability by itself.
  • Exact FDA submission
  • Checked 2026-09-03

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, and outputs to K230082 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

Server-based automated DICOM CT ingestion and RTSS export to predefined destinations; test scanner protocols, contrast, slice spacing, structure naming, routing, TPS import, and failure quarantine.

exact submission · checked 2026-09-03

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The software is for adults and initial segmentation only. Users must verify every contour and label; average Dice varies greatly by structure and does not predict local editing burden or dosimetric acceptability by itself.

exact submission · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-03

Vendor productivity claims are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: The software is for adults and initial segmentation only. Users must verify every contour and label; average Dice varies greatly by structure and does not predict local editing burden or dosimetric acceptability by itself.

exact submission · checked 2026-09-03

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K230082
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Radiotherapy Planning Imaging
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Anatomy
Multi-region
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2023-05-04
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
11Source classes checked
20Screened PubMed leads
10Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 20 PubMed and 10 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 20 PubMed and 10 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, vendor product page, reimbursement policy, fda device recall, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

8 sources - 3 history items

Source ledger

  1. FDA K230082: Auto Segmentation

    U.S. Food and Drug Administration - Published 2023-05-04 - Accessed 2026-09-19

    Scope: purpose, modality, anatomy, intendedUsers, input, output, limitations, evidenceSummary, clinicalUse

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  6. Radiation Oncology Model

    Centers for Medicare & Medicaid Services - Accessed 2026-09-02

    Scope: reimbursement, radiationTherapyPaymentContext

  7. Auto Segmentation for radiation therapy planning

    GE HealthCare - Accessed 2026-09-03

    Scope: productFamily, workflowRole, integration, implementationCapabilities, currentCommercialContext

  8. GE HealthCare: Product Security (portal and Cybersecurity Risk Management System)

    GE HealthCare - Accessed 2026-10-26

    Scope: security

Research history

  1. K230082 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K232928

DeepContour (V1.0)

Wisdom Technologies., Inc.

Authorized purpose: DeepContour uses deep-learning CT processing to generate editable organ contours and RTSTRUCT objects for selected adult radiation-treatment planning workflows, with quantitative statistics, registration, and three-dimensional visualization; it does not contour tumors.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2024-05-07
FDA-cleared K222312

RayStation 12A

RaySearch Laboratories AB (publ)

Authorized purpose: RayStation 12A is configurable software for radiation therapy and medical oncology that proposes treatment plans from user input. Authorized users may use reviewed and approved plans to support treatment administration; the system includes image handling, contouring, treatment planning and optimization, dose calculation and evaluation, machine commissioning, treatment interfaces, and machine-learning segmentation or planning functions.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2023-03-29
FDA-cleared K211881

AI Segmentation

Varian Medical Systems, Inc.

Authorized purpose: AI Segmentation version 2.0 is a cloud web application that generates initial CT organ-at-risk contours for head and neck, thorax, abdomen, and pelvis for review, editing, and approval in Eclipse treatment-planning workflows; it does not provide clinical decisions or evaluate treatment plans.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2021-09-02
FDA-cleared K203469

AI Segmentation

Varian Medical Systems, Inc.

Authorized purpose: AI Segmentation version 1.0 is a static, cloud-hosted web application that generates initial CT organ-at-risk contours for head and neck, thorax, abdomen, and pelvis for review and approval in Eclipse treatment-planning workflows; this release does not include manual editing tools.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2021-04-19

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history